This story originally ran on Oct. 20.

Danaher reported this week that revenues for its AB Sciex business grew at low double-digit rates in the third quarter, driven by continued demand for the company's TripleTOF 5600 mass spectrometer.

On a conference call to discuss the earnings report, Danaher CEO Larry Culp called AB Sciex's performance a "gangbuster quarter" and noted that demand for mass spectrometers was broad based, with academic, research, and applied markets all growing in excess of 10 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.